STOCKSCOPE

Big River Industries (ASX: BRI) Secures $156 Million Takeover Deal at 45.9% Premium as Earnings Recovery Gains Momentum

Alison Elzayed

Alison Elzayed

Business & Finance Writer | StockScope

Published:12h ago
Big River Industries (ASX: BRI) Secures $156 Million Takeover Deal at 45.9% Premium as Earnings Recovery Gains Momentum

Big River Industries (ASX: BRI) has secured a $1.62-per-share cash takeover proposal, valuing the building products manufacturer and distributor at approximately $156 million.

The agreement represents a 45.9% premium to its closing share price on 12 November 2026 and comes as the company delivers improving revenue, stronger margins and growing earnings.

The combination of a substantial takeover premium and improving business fundamentals highlights the value emerging from Big River's operational recovery.

Key Numbers

  • $1.62 per share: Cash consideration under the proposed takeover scheme.
  • 45.9% premium: Compared with the closing share price of $1.11 on 12 November 2026.
  • $156 million: Approximate equity valuation, with enterprise value estimated at $216 million.
  • 59.5%: Combined shareholding of Anacacia and NAOS-managed funds, which intend to support the transaction subject to conditions.
  • $31.1 million: FY26 underlying EBITDA, up 8.4% year-on-year.

Latest Development: Binding Agreement Unlocks Shareholder Value

On 13 November 2026, Big River announced a binding Scheme Implementation Deed with CTL, marking a significant step towards a potential change of ownership.

CTL, which already holds approximately 19.9% of Big River, proposes to acquire the remaining shares through a scheme of arrangement.

The $1.62 cash consideration represents a 47.2% premium to the one-month volume-weighted average price of $1.10 and a 35.0% premium to the three-month average of $1.20.

The agreement also allows Big River to distribute a fully franked special dividend of up to $0.21 per share, with any payment reducing the cash scheme consideration by an equivalent amount.

The board unanimously recommends the transaction, subject to an independent expert concluding it is in shareholders' best interests and no superior proposal emerging.

What Stands Out: Stronger Financial Performance Supports the Deal

The proposed acquisition arrives as Big River demonstrates improving operational momentum.

FY26 revenue increased 5.3% to $426.4 million, while underlying EBITDA climbed 8.4% to $31.1 million.

Momentum continued into FY27, with first-quarter revenue rising 10.5% to $117.6 million and gross margins improving 40 basis points to 26.7%.

These results highlight the company's ability to grow despite subdued residential construction conditions.

At the estimated $216 million enterprise valuation, including lease liabilities, the transaction implies approximately 6.9 times FY26 underlying EBITDA.

This provides a useful transaction reference, although differences in lease accounting must be considered when comparing valuation multiples.

Importantly, the substantial takeover premium provides shareholders with a defined cash outcome while recognising the progress achieved through Big River's operational improvement programme.

What the Company Is Doing Now

Big River continues strengthening its position across specialist building products, timber manufacturing and national distribution.

The company is expanding higher-value categories including cladding, specialist plywood and decorative panels, supporting product diversification and margin improvement.

Its acquisition of Johns Building Supplies has strengthened its Western Australian operations, contributing $25.2 million in FY26 revenue.

Alongside these initiatives, Big River is improving manufacturing efficiency, procurement arrangements and working capital management.

These efforts provide a stronger operational foundation as the proposed transaction advances through the required approvals.

Insight: A Strong Premium Reflects Improving Business Fundamentals

We view the proposed acquisition as a positive development that recognises Big River's improving financial performance and established market position. The 45.9% premium offers shareholders a substantial uplift to the unaffected trading price, while recent revenue growth and margin expansion demonstrate the underlying business's improving strength. Its manufacturing capabilities, distribution network and growing specialist product portfolio provide additional commercial value. Although the transaction remains conditional, support from major shareholders and the board strengthens its prospects. The agreed consideration provides a clear valuation benchmark while Big River continues its earnings recovery.

What Happens Next?

The proposed acquisition is targeted for completion during the first quarter of calendar 2027.

Key milestones include ACCC clearance, shareholder approval, Court approval and a favourable independent expert assessment.

CTL expects to fund the acquisition through existing cash reserves and committed debt financing, with no financing condition attached.

Meanwhile, Big River's continuing operational improvements and FY27 earnings momentum provide an encouraging backdrop to the transaction.

With a binding agreement, substantial takeover premium and improving financial performance, Big River enters its next chapter with a clearer pathway towards delivering value for shareholders.

Alison Elzayed

Alison Elzayed

(Business & Finance Writer | StockScope)

Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Sells Off as Paladin Slumps 17%: Rising Bond Yields and NVIDIA Shock Rattle Global Markets
Market Briefings
Market Briefings

ASX Sells Off as Paladin Slumps 17%: Rising Bond Yields and NVIDIA Shock Rattle Global Markets

Australian equities: what moved the ASX 200? Australian shares finished Friday, 13 November, under pressure, with the S&P/ASX 200 falling 65.4 points, or 0.71%, to close at 9,082.2. The in...

Mark ElzayedMark Elzayed•
Carma (ASX: CMA) Doubles Gross Profit as Vehicle Sales Surge, Setting the Stage for Its Next Growth Phase
Consumer
Consumer

Carma (ASX: CMA) Doubles Gross Profit as Vehicle Sales Surge, Setting the Stage for Its Next Growth Phase

Carma Limited ASX: CMA is building momentum in Australia's online used-car market, with annual gross profit more than doubling and vehicle sales surging 86%. Its 13 November 2026 annual gene...

Alison ElzayedAlison Elzayed•
Imricor Medical Systems (ASX: IMR) Sees US Revenue Surge 437% as Hospital Expansion Opens New Growth Opportunities
Biotech & Health
Biotech & Health

Imricor Medical Systems (ASX: IMR) Sees US Revenue Surge 437% as Hospital Expansion Opens New Growth Opportunities

Imricor Medical Systems ASX: IMR is gaining commercial momentum in the United States, with September-quarter revenue climbing 437% as its innovative cardiac technology begins generating s...

Danny AadDanny Aad•
Neurizon Therapeutics (ASX: NUZ) Advances ALS Treatment Towards Pivotal 2027 Results as $12 Million Funding Facility Strengthens Outlook
Biotech & Health
Biotech & Health

Neurizon Therapeutics (ASX: NUZ) Advances ALS Treatment Towards Pivotal 2027 Results as $12 Million Funding Facility Strengthens Outlook

Neurizon Therapeutics ASX: NUZ is building momentum towards a potentially transformative clinical milestone, with two developments on 13 November 2026 strengthening its position ahead of piv...

Danny AadDanny Aad•
Artrya (ASX: AYA) Secures Fifth US Hospital Deal as Commercial Momentum Builds in $580 Million Growth Story
Biotech & Health
Biotech & Health

Artrya (ASX: AYA) Secures Fifth US Hospital Deal as Commercial Momentum Builds in $580 Million Growth Story

Artrya Limited ASX: AYA is gaining momentum in the US healthcare market, securing a five-year agreement with Arizona-based HonorHealth worth at least US$500,000. The 13 November announcemen...

Danny AadDanny Aad•
Omega Oil & Gas (ASX: OMA) Hits Gas at Queensland’s Deepest Well as Taroom Trough Opportunity Grows
Energy
Energy

Omega Oil & Gas (ASX: OMA) Hits Gas at Queensland’s Deepest Well as Taroom Trough Opportunity Grows

Gas reaching the surface and the highest gas shows recorded to date have added fresh momentum to Omega Oil & Gas Limited ASX: OMA, strengthening the emerging resource story in Queensland’s T...

Alison ElzayedAlison Elzayed•
Loading more stories...